You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

Pipeline date and pdf

Pipeline Snapshot as of October 29, 2019

  • Discovery Projects
  • Phase 1
    26
  • Phase 2
    37
  • Phase 3
    24
  • Registration
    9
  • Total96
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Combo w/ Talzenna (talazoparib) and binimetinib for Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
Cancer (Biologic) Phase 1 Product Enhancement Biologic
Inlyta (axitinib)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
VEGF Tyrosine Kinase Inhibitor
Go to clinical trial
Combo w/ Merck's Keytruda® (PD-1, pembrolizumab) for: Cancer Phase 1 Product Enhancement Small Molecule
PF-04447943
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
PDE9 Inhibitor
Go to clinical trial
Sickle Cell Anemia (ORPHAN - U.S.) Phase 1 New Molecular Entity Small Molecule
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
CD137 Agonist
Go to clinical trial
Combo w/Kite Pharma's Axicabtagene Ciloleucel for Cancer
Project advanced
Phase 1 New Molecular Entity Biologic
PF-05230907
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Factor Xa Protein Replacement
Go to clinical trial
Intracerebral Hemorrhage (Biologic) (ORPHAN - U.S.) Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06688992
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06753512
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06755347
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Immunomodulation
Go to clinical trial
Chronic Inflammatory Demyelination Polyneuropathy Phase 1 New Molecular Entity Biologic
PF-06801591
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Cancer Immunotherapy (Biologic) Phase 1 New Molecular Entity Biologic
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
HER2 Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06826647
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2 Inhibitor
Go to clinical trial
Inflammatory Bowel Disease Phase 1 Product Enhancement Small Molecule
PF-06835375
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
chemokine inhibitor
Go to clinical trial
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Go to clinical trial
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 1 New Molecular Entity Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Go to clinical trial
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule